Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-12-22 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
2025年第三次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2025 Third Extraordinary General Meeting of Shareholders" of 科兴生物制药股份有限公司. It includes detailed meeting instructions, agenda, and proposals to be voted on at the meeting, such as changes in use of raised funds and the reappointment of the 2025 audit firm. The content is clearly related to the preparation and information for a shareholders meeting rather than the meeting minutes or voting results. It is not a full annual report, audit report, or financial statement. The document is a presentation or materials shared for the shareholders meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length (5325 characters) and detailed agenda and proposals support this classification with high confidence.
2025-12-22 Chinese
关于变更部分募集资金用途及部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about changes in the use of part of its raised funds and the extension of some investment projects. It discusses the reallocation of funds from one project to another, the reasons for these changes, project progress, and approvals by the board and sponsors. The document references the company's initial public offering and fundraising, specific project investment amounts, and regulatory approvals. It is not a full annual or interim financial report, nor is it a simple announcement of a report. It is a detailed disclosure about changes in capital use and project timelines, which fits the definition of a Capital/Financing Update (CAP). The document is substantive and over 12,000 characters, so it is not a mere announcement or regulatory filing. Therefore, the best classification is CAP.
2025-12-15 Chinese
关于召开2025年第三次临时股东会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2025 third extraordinary general meeting of shareholders (临时股东会) for 科兴生物制药股份有限公司. It details the meeting date, voting methods, agenda items, registration procedures, and includes an authorization proxy form for voting. There is no financial data, earnings, or report content included. The document is an announcement of a shareholders meeting, not a report or transcript. It fits the category of AGM Information (AGM-R) as it provides materials and notices related to the Annual or Extraordinary General Meeting.
2025-12-15 Chinese
关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (致同会计师事务所) for auditing services for the fiscal year 2025. It details the firm's background, personnel, independence, audit fees, and the approval process by the audit committee and board of directors. There are no actual financial statements or audit reports included, only information about the appointment process and firm credentials. The document length is 2478 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates to audit firm appointment and audit-related information, but it is not a full audit report or annual report itself. FY 2025
2025-12-15 Chinese
自愿披露关于眼科制剂GB10注射液获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by the company regarding the approval of a clinical trial for a new drug (GB10 injection) by the National Medical Products Administration (国家药品监督管理局). It describes the clinical trial approval, product details, and potential impact on the company. The document is short (1157 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory approval event related to drug development, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-12-08 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 科兴生物制药股份有限公司 regarding the progress of its share repurchase program through centralized bidding transactions. It details the repurchase plan, including dates, amounts, prices, and cumulative shares repurchased. The document does not contain financial statements or detailed financial analysis but provides updates on the company's share buyback activities. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares. The document length is 1739 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is POS.
2025-12-02 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.